OBJECTIVES: Ischemia-reperfusion injury contributes significantly to morbidity and mortality in lung transplant patients. Currently, no therapeutic agents are clinically available to prevent ischemia-reperfusion injury, and treatment strategies are limited to maintaining oxygenation and lung function. Adenosine can modulate inflammatory activity and injury by binding to various adenosine receptors; however, the role of the adenosine A1 receptor in ischemia-reperfusion injury and inflammation is not well understood. The present study tested the hypothesis that selective, exogenous activation of the A1 receptor would be anti-inflammatory and attenuate lung ischemia-reperfusion injury. METHODS: Wild-type and A1 receptor knockout mice underwent 1 hour of left lung ischemia and 2 hours of reperfusion using an in vivo hilar clamp model. An A1 receptor agonist, 2-chloro-N6-cyclopentyladenosine, was administered 5 minutes before ischemia. After reperfusion, lung function was evaluated by measuring airway resistance, pulmonary compliance, and pulmonary artery pressure. The wet/dry weight ratio was used to assess edema. The myeloperoxidase and cytokine levels in bronchoalveolar lavage fluid were measured to determine the presence of neutrophil infiltration and inflammation. RESULTS: In the wild-type mice, 2-chloro-N6-cyclopentyladenosine significantly improved lung function and attenuated edema, cytokine expression, and myeloperoxidase levels compared with the vehicle-treated mice after ischemia-reperfusion. The incidence of lung ischemia-reperfusion injury was similar in the A1 receptor knockout and wild-type mice; and 2-chloro-N6-cyclopentyladenosine had no effects in the A1 receptor knockout mice. In vitro treatment of neutrophils with 2-chloro-N6-cyclopentyladenosine significantly reduced chemotaxis. CONCLUSIONS: Exogenous A1 receptor activation improves lung function and decreases inflammation, edema, and neutrophil chemotaxis after ischemia and reperfusion. These results suggest a potential therapeutic application for A1 receptor agonists for the prevention of lung ischemia-reperfusion injury after transplantation.
OBJECTIVES:Ischemia-reperfusion injury contributes significantly to morbidity and mortality in lung transplant patients. Currently, no therapeutic agents are clinically available to prevent ischemia-reperfusion injury, and treatment strategies are limited to maintaining oxygenation and lung function. Adenosine can modulate inflammatory activity and injury by binding to various adenosine receptors; however, the role of the adenosine A1 receptor in ischemia-reperfusion injury and inflammation is not well understood. The present study tested the hypothesis that selective, exogenous activation of the A1 receptor would be anti-inflammatory and attenuate lung ischemia-reperfusion injury. METHODS: Wild-type and A1 receptor knockout mice underwent 1 hour of left lung ischemia and 2 hours of reperfusion using an in vivo hilar clamp model. An A1 receptor agonist, 2-chloro-N6-cyclopentyladenosine, was administered 5 minutes before ischemia. After reperfusion, lung function was evaluated by measuring airway resistance, pulmonary compliance, and pulmonary artery pressure. The wet/dry weight ratio was used to assess edema. The myeloperoxidase and cytokine levels in bronchoalveolar lavage fluid were measured to determine the presence of neutrophil infiltration and inflammation. RESULTS: In the wild-type mice, 2-chloro-N6-cyclopentyladenosine significantly improved lung function and attenuated edema, cytokine expression, and myeloperoxidase levels compared with the vehicle-treated mice after ischemia-reperfusion. The incidence of lung ischemia-reperfusion injury was similar in the A1 receptor knockout and wild-type mice; and 2-chloro-N6-cyclopentyladenosine had no effects in the A1 receptor knockout mice. In vitro treatment of neutrophils with 2-chloro-N6-cyclopentyladenosine significantly reduced chemotaxis. CONCLUSIONS: Exogenous A1 receptor activation improves lung function and decreases inflammation, edema, and neutrophil chemotaxis after ischemia and reperfusion. These results suggest a potential therapeutic application for A1 receptor agonists for the prevention of lung ischemia-reperfusion injury after transplantation.
Authors: Leo M Gazoni; Dustin M Walters; Eric B Unger; Joel Linden; Irving L Kron; Victor E Laubach Journal: J Thorac Cardiovasc Surg Date: 2010-04-15 Impact factor: 5.209
Authors: Chun-Xiao Sun; Hays W Young; Jose G Molina; Jonathan B Volmer; Jurgen Schnermann; Michael R Blackburn Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: A R Heller; J Rothermel; M A Weigand; K Plaschke; J Schmeck; M Wendel; H J Bardenheuer; T Koch Journal: Eur J Anaesthesiol Date: 2006-11-10 Impact factor: 4.330
Authors: Ashish K Sharma; Victor E Laubach; Susan I Ramos; Yunge Zhao; George Stukenborg; Joel Linden; Irving L Kron; Zequan Yang Journal: J Thorac Cardiovasc Surg Date: 2009-11-11 Impact factor: 5.209
Authors: Jingang Zheng; Rubio Wang; Edward Zambraski; Dan Wu; Kenneth A Jacobson; Bruce T Liang Journal: Am J Physiol Heart Circ Physiol Date: 2007-10-05 Impact factor: 4.733
Authors: Vijay B Urmaliya; Jarrod E Church; Ian M Coupar; Roselyn B Rose'Meyer; Colin W Pouton; Paul J White Journal: J Cardiovasc Pharmacol Date: 2009-05 Impact factor: 3.105
Authors: Minjae Kim; Sean W C Chen; Sang Won Park; Mihwa Kim; Vivette D D'Agati; Jay Yang; H Thomas Lee Journal: Kidney Int Date: 2009-02-04 Impact factor: 10.612
Authors: Walker M McHugh; William W Russell; Andrew J Fleszar; Paul E Rodenhouse; Skyler P Rietberg; Lei Sun; Thomas P Shanley; Timothy T Cornell Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-09-16 Impact factor: 5.464
Authors: Manmeet Bhalla; Jun Hui Yeoh; Claire Lamneck; Sydney E Herring; Essi Y I Tchalla; Lauren R Heinzinger; John M Leong; Elsa N Bou Ghanem Journal: Cell Microbiol Date: 2019-11-20 Impact factor: 3.715
Authors: Mary E Huerter; Ashish K Sharma; Yunge Zhao; Eric J Charles; Irving L Kron; Victor E Laubach Journal: Ann Thorac Surg Date: 2016-04-22 Impact factor: 4.330
Authors: Constance N Wilson; Constance O Vance; Melissa G Lechner; George M Matuschak; Andrew J Lechner Journal: Eur J Pharmacol Date: 2014-07-18 Impact factor: 4.432
Authors: Elsa N Bou Ghanem; Stacie Clark; Sara E Roggensack; Sally R McIver; Pilar Alcaide; Philip G Haydon; John M Leong Journal: PLoS Pathog Date: 2015-08-27 Impact factor: 6.823
Authors: Saverio La Francesca; Anthony E Ting; Jason Sakamoto; Jessica Rhudy; Nicholas R Bonenfant; Zachary D Borg; Fernanda F Cruz; Meagan Goodwin; Nicholas A Lehman; Jennifer M Taggart; Robert Deans; Daniel J Weiss Journal: Transplant Res Date: 2014-11-01